In a small, short-term, Phase 2 clinical trial in adults, a first-of-its-kind medication reduced triglyceride levels in most ...
Merck’s Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback